GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities

About this update from Gentian Diagnostics Asa

Q1 sales were flat at NOK 43.9 million, with 4% organic growth and strong U.S. and European performance. NT-proBNP assay development was discontinued, leading to a NOK 30 million impairment, but resources are being reallocated to a robust pipeline. Confidence remains high for double-digit growth in 2024.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Gentian Diagnostics Asa